• Science and Research

  ABBV-2222 Partly Corrects CFTR Function in CF Patients, Phase 2 Data Show

  Posted by cystic-fibrosis-news-moderator on June 4, 2019 at 9:11 am

  ABBV-2222 partially corrected the function of CFTR in CF patients, both alone and in combination with Kalydeco, two Phase 2 trials show. Read more about these findings here.

  What do you think of this news?

  cystic-fibrosis-news-moderator replied 4 years, 10 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply